Owkin

🚀 Owkin Launches K Pro at ESMO 2025! We’re unveiling K Pro – the first agentic AI co-pilot for biopharma powered by advanced biological reasoning models. K Pro is built on 10 years of Owkin’s AI innovation. It empowers pharma, biotech, and investors to make smarter, faster decisions across the R&D pipeline. K Pro combines: • Natural language interaction for querying complex biological questions • High-quality, multimodal biomedical data – curated, integrated, and AI-ready • Agentic AI that delivers, analysis, visualizations, and actionable clinical insights in moments, not months At its core, K Pro integrates OwkinZero - our pioneering biological large language model to perform high-level biological reasoning - and unifies fragmented workflows for both scientists and executives. Find the press release here: owkin.com/newsfeed/owkin… 🔗 Visit us at ESMO booth #4021 to learn more about how K Pro is changing the game for biopharma decision-making or book a meeting with our team here: calendly.com/esmo-2025

We sit down with our Chief Medical Officer, Dr. Caroline Hoffmann, to discuss her journey from surgical oncology to AI-powered biomedical research and why she believes clinicians need to play an active role in shaping the future of AI in medicine.

New on bioRxiv: We identify PRDX5 as a subtype-specific target in malignant pleural mesothelioma. ML-guided virtual screen of 3.6M compounds against cryptic allosteric pockets → 36 non-covalent hits, sub-µM inhibitors. 8% hit rate vs ~1% in typical HTS. biorxiv.org/content/10.648…

📢 Announcing our new deal to build AI agents as part of a multi-year K Pro license agreement with @AstraZeneca Read the full press release here owkin.com/newsfeed/owkin…

Peer-reviewed in BMC Medical Research Methodology: we benchmark 9 subgroup analysis methods for time-to-event RCTs. Interaction tests detect heterogeneity; ML-based CATE estimators identify good responders. link.springer.com/article/10.118…

"I think ultimately the whole conference should probably be about AI." — Pr. Jakob Kather at AACR 2026. Our recap of the meeting where foundation models, agentic systems, and the implementation gap took center stage: owkin.com/blogs-case-stu…

🎙️We sit down with our Chief Corporate Dev & Ops Strategy Officer @ Anna HD to get her take on Owkin’s mission with K Pro and how we work in an ecosystem alongside tech players such as Anthropic and OpenAI. Learn more about K Pro: owkin.com/k-os/k-pro

💊 AI scientists can now tackle drug R&D. What does that mean for pharma? Our Co-CEO Pascal Weinberger discusses how AI agents are transforming drug discovery, featured in @PharmaVoice. Read article here: pharmavoice.com/news/ai-pharma… Learn about K Pro → owkin.com/k-os/k-pro

📢 Great to be highlighted at the AWS conference by Dan Sheeran last week - Dan foregrounded how: Book your demo of K Pro here -> owkin.com/connect/book-a…

👀 In case you missed it on Friday - our CEO @TClozel has published this editorial in @FastCompany: why AI needs a reality check. 📰 Read it here fastcompany.com/91529003/ai-ne…

🎤 We're at AACR 2026 — find us at booth 4616 for K Pro demos and conversations with the team. Monday April 20: don't miss our spotlight talk on "AI Agent for Pharma R&D" with Dr. Caroline Hoffmann and Jonas Béal!

Why do 90% of ADC trials fail? Tumors aren't just cell clusters - they're defensive ecosystems. At Owkin, we use spatial biology + K Pro to map tumor geography, engineer dual-lock targets, and design context-aware ADCs. owkin.com/blogs-case-stu…

New preprint: Can AI agents learn from lab experiments? Our agents select & adapt gene knockouts to generate phenotypical responses - discovering 166% more targets than random selection. Model capability was key: Sonnet 4.6 enabled learning; 4.5 didn't. owkin.com/blogs-case-stu…

New preprint: CytoSyn, a foundation diffusion model for histopathology. Generates diverse and highly realistic synthetic tissue images using H0-mini’s embeddings as conditioning. Paper: arxiv.org/abs/2603.18089 Model: huggingface.co/Owkin-Bioptimu…

New preprint: CytoSyn, a foundation diffusion model for histopathology. Generates diverse and highly realistic synthetic tissue images using H0-mini’s embeddings as conditioning. Paper: arxiv.org/abs/2603.18089 Model: huggingface.co/Owkin-Bioptimu…

🎙️ We sit down with our Chief Financial Officer Graeme Bell to get his take on Owkin’s funding strategy and the value proposition of K Pro. Learn more about K Pro: owkin.com/k-os/k-pro

As part two of our Woman in Tech Spotlight Series, we’re featuring our Head of Platform Biology, @ Roberta Codato, who shares a powerful reminder: your voice matters. Follow along as we continue to highlight the women shaping Owkin!

Preprint on bioRxiv: 1st comprehensive multi-modal benchmark of Ultima UG100 vs Illumina NovaSeq on FFPE tissues. Preprint: biorxiv.org/content/10.648… Code: github.com/owkin/ultilumi…

We just trained an AI to come up with novel therapeutic hypotheses, and it outperformed GPT-5. Find out more in our blog: owkin.com/blogs-case-stu…

🚀 Join us at Start Summit this week Our Chief Medical Officer, Dr. Caroline Hoffmann, will sit down with Dr. Friederike Hoffmann, Partner at b2venture, for a fireside chat on “Prompt. Protein. Patient.” 🔎 Learn more: startglobal.org/start-summit

🎙️ We continue our sit down session with our Chief Research & Development Officer Eric Durand to understand Owkin’s K Pro infrastructure, as well as our ongoing work building our AI scientist. Learn more about K Pro: owkin.com/k-os/k-pro